piracetam, rivastigmine and their joint consumption effects on mmse score status in patients with alzheimer's disease

alzheimer's disease is considered the most common cause of dementia. at present, no definite cure is available for healing the disorders and stopping the disease progress. the aim of this study is to study the effects of piracetam, rivastigmine and their joint consumption on mmse score status in patients with alzheimer disease. this interventional study was carried out on 64 patients with alzheimer's disease. they were randomly divided into four groups. the first group was treated with piracetam 800 mg daily. the second group was treated with rivastigmine 3 mg daily. the third group used a combination of both drugs; and the fourth group has taken placebo. at the beginning of the experiment and at the end of the third month, all patients underwent mmse. the results were statistically analyzed. in this study 32 patients were male. a significant difference was found between rivastigmine group and control group ( p < 0.01) and between control group and the group who had received a combination of both drugs ( p < 0.02). in summary, the findings of this study showed that treatment with rivastigmine or combination of rivastigmine and piracetam can improve clinical symptoms in these patients, but piracetam alone has no effect in the patients.